Forty quarters equals 400
This article was originally published in Scrip
Executive Summary
Scrip's most recent analysis of long-term trends in pharma innovation, Reaping in due season? R&D trends and novel drug launches, shows that the number of truly original cancer drugs launched per year has more than doubled in a decade – from around four per year in 2000-2003 to nearly 10 per year in 2010-12. But in CNS that number has halved in the period – from six to just over three.